Delivery of nVEGFi using AAV8 for the treatment of neovascular age-related macular degeneration

Delivery of nVEGFi using AAV8 for the treatment of neovascular age-related macular degeneration

Inhibition of vascular endothelial growth factor (VEGF) is the standard therapy for neovascular age-related macular degeneration (nAMD). However, anti-VEGF agents used in the clinic require repeated injections, causing adverse effects. Gene therapy could provide sustained anti-VEGF levels after a si...

Full description

Bibliographic Details
Main Authors: Kaiqin She, Jing Su, Qingnan Wang, Yi Liu, Xiaomei Zhong, Xiu Jin, Qinyu Zhao, Jianlu Xiao, Ruiting Li, Hongxin Deng, Fang Lu, Yang Yang, Yuquan Wei
Format: Article
Language:English
Published: Elsevier 2022-03-01
Series:Molecular Therapy: Methods & Clinical Development
Subjects:
neovascular age-related macular degeneration
anti-vascular endothelial growth factor
choroidal neovascularization
VEGF trap
gene therapy
adeno-associated virus
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050122000031

Internet

http://www.sciencedirect.com/science/article/pii/S2329050122000031

Similar Items